206 related articles for article (PubMed ID: 21672334)
21. Comparison of the effect of alendronate on lumbar bone mineral density and bone turnover in men and postmenopausal women with osteoporosis.
Iwamoto J; Takeda T; Sato Y; Uzawa M
Clin Rheumatol; 2007 Feb; 26(2):161-7. PubMed ID: 16565894
[TBL] [Abstract][Full Text] [Related]
22. Prevention of glucocorticoid induced osteoporosis with alendronate or alfacalcidol: relations of change in bone mineral density, bone markers, and calcium homeostasis.
Jacobs JW; de Nijs RN; Lems WF; Geusens PP; Laan RF; Huisman AM; Algra A; Buskens E; Hofbauer LC; Oostveen AC; Bruyn GA; Dijkmans BA; Bijlsma JW
J Rheumatol; 2007 May; 34(5):1051-7. PubMed ID: 17407214
[TBL] [Abstract][Full Text] [Related]
23. Positive effect of alendronate on bone mineral density and markers of bone turnover in patients with rheumatoid arthritis on chronic treatment with low-dose prednisone: a randomized, double-blind, placebo-controlled trial.
Lems WF; Lodder MC; Lips P; Bijlsma JW; Geusens P; Schrameijer N; van de Ven CM; Dijkmans BA
Osteoporos Int; 2006; 17(5):716-23. PubMed ID: 16463007
[TBL] [Abstract][Full Text] [Related]
24. Effect of denosumab on bone mineral density and biochemical markers of bone turnover: 8-year results of a phase 2 clinical trial.
McClung MR; Lewiecki EM; Geller ML; Bolognese MA; Peacock M; Weinstein RL; Ding B; Rockabrand E; Wagman RB; Miller PD
Osteoporos Int; 2013 Jan; 24(1):227-35. PubMed ID: 22776860
[TBL] [Abstract][Full Text] [Related]
25. Effects of denosumab on bone mineral density and bone turnover in postmenopausal women transitioning from alendronate therapy.
Kendler DL; Roux C; Benhamou CL; Brown JP; Lillestol M; Siddhanti S; Man HS; San Martin J; Bone HG
J Bone Miner Res; 2010 Jan; 25(1):72-81. PubMed ID: 19594293
[TBL] [Abstract][Full Text] [Related]
26. Two-year results of once-weekly administration of alendronate 70 mg for the treatment of postmenopausal osteoporosis.
Rizzoli R; Greenspan SL; Bone G; Schnitzer TJ; Watts NB; Adami S; Foldes AJ; Roux C; Levine MA; Uebelhart B; Santora AC; Kaur A; Peverly CA; Orloff JJ;
J Bone Miner Res; 2002 Nov; 17(11):1988-96. PubMed ID: 12412806
[TBL] [Abstract][Full Text] [Related]
27. Effect of alendronate on glucocorticoid-induced osteoporosis in Japanese women with systemic autoimmune diseases: versus alfacalcidol.
Takeda S; Kaneoka H; Saito T
Mod Rheumatol; 2008; 18(3):271-6. PubMed ID: 18427724
[TBL] [Abstract][Full Text] [Related]
28. Potential of alfacalcidol for reducing increased risk of falls and fractures.
Ringe JD; Schacht E
Rheumatol Int; 2009 Aug; 29(10):1177-85. PubMed ID: 19159932
[TBL] [Abstract][Full Text] [Related]
29. A comparison of the effects of alendronate and alfacalcidol on bone mineral density around the femoral implant and in the lumbar spine after total hip arthroplasty.
Iwamoto N; Inaba Y; Kobayashi N; Ishida T; Yukizawa Y; Saito T
J Bone Joint Surg Am; 2011 Jul; 93(13):1203-9. PubMed ID: 21776573
[TBL] [Abstract][Full Text] [Related]
30. Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial.
Black DM; Schwartz AV; Ensrud KE; Cauley JA; Levis S; Quandt SA; Satterfield S; Wallace RB; Bauer DC; Palermo L; Wehren LE; Lombardi A; Santora AC; Cummings SR;
JAMA; 2006 Dec; 296(24):2927-38. PubMed ID: 17190893
[TBL] [Abstract][Full Text] [Related]
31. Multinational, placebo-controlled, randomized trial of the effects of alendronate on bone density and fracture risk in postmenopausal women with low bone mass: results of the FOSIT study. Fosamax International Trial Study Group.
Pols HA; Felsenberg D; Hanley DA; Stepán J; Muñoz-Torres M; Wilkin TJ; Qin-sheng G; Galich AM; Vandormael K; Yates AJ; Stych B
Osteoporos Int; 1999; 9(5):461-8. PubMed ID: 10550467
[TBL] [Abstract][Full Text] [Related]
32. Teriparatide or alendronate in glucocorticoid-induced osteoporosis.
Saag KG; Shane E; Boonen S; Marín F; Donley DW; Taylor KA; Dalsky GP; Marcus R
N Engl J Med; 2007 Nov; 357(20):2028-39. PubMed ID: 18003959
[TBL] [Abstract][Full Text] [Related]
33. Effects of teriparatide, alendronate, or both in women with postmenopausal osteoporosis.
Finkelstein JS; Wyland JJ; Lee H; Neer RM
J Clin Endocrinol Metab; 2010 Apr; 95(4):1838-45. PubMed ID: 20164296
[TBL] [Abstract][Full Text] [Related]
34. Additional beneficial effects of alendronate in growth hormone (GH)-deficient adults with osteoporosis receiving long-term recombinant human GH replacement therapy: a randomized controlled trial.
Biermasz NR; Hamdy NA; Janssen YJ; Roelfsema F
J Clin Endocrinol Metab; 2001 Jul; 86(7):3079-85. PubMed ID: 11443170
[TBL] [Abstract][Full Text] [Related]
35. Comparison of alendronate and raloxifene in postmenopausal women with osteoporosis.
Sanad Z; Ellakwa H; Desouky B
Climacteric; 2011 Jun; 14(3):369-77. PubMed ID: 21254911
[TBL] [Abstract][Full Text] [Related]
36. Prevention of bone loss after withdrawal of tamoxifen.
Cohen A; Fleischer JB; Johnson MK; Brown IN; Joe AK; Hershman DL; McMahon DJ; Silverberg SJ
Endocr Pract; 2008 Mar; 14(2):162-7. PubMed ID: 18308653
[TBL] [Abstract][Full Text] [Related]
37. Effects of morning vs. evening teriparatide injection on bone mineral density and bone turnover markers in postmenopausal osteoporosis.
Michalska D; Luchavova M; Zikan V; Raska I; Kubena AA; Stepan JJ
Osteoporos Int; 2012 Dec; 23(12):2885-91. PubMed ID: 22426952
[TBL] [Abstract][Full Text] [Related]
38. Skeletal benefits of two years of alendronate treatment are similar for early postmenopausal Asian and Caucasian women.
Wasnich RD; Ross PD; Thompson DE; Cizza G; Yates AJ
Osteoporos Int; 1999; 9(5):455-60. PubMed ID: 10550466
[TBL] [Abstract][Full Text] [Related]
39. Therapeutic equivalence of alendronate 70 mg once-weekly and alendronate 10 mg daily in the treatment of osteoporosis. Alendronate Once-Weekly Study Group.
Schnitzer T; Bone HG; Crepaldi G; Adami S; McClung M; Kiel D; Felsenberg D; Recker RR; Tonino RP; Roux C; Pinchera A; Foldes AJ; Greenspan SL; Levine MA; Emkey R; Santora AC; Kaur A; Thompson DE; Yates J; Orloff JJ
Aging (Milano); 2000 Feb; 12(1):1-12. PubMed ID: 10746426
[TBL] [Abstract][Full Text] [Related]
40. Effects of discontinuing oral bisphosphonate treatments for postmenopausal osteoporosis on bone turnover markers and bone density.
Naylor KE; Bradburn M; Paggiosi MA; Gossiel F; Peel NFA; McCloskey EV; Walsh JS; Eastell R
Osteoporos Int; 2018 Jun; 29(6):1407-1417. PubMed ID: 29525970
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
